Marquette Asset Management LLC Acquires Shares of 33,311 Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Marquette Asset Management LLC bought a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 33,311 shares of the biotechnology company’s stock, valued at approximately $81,000. Marquette Asset Management LLC owned 0.08% of Oramed Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. BML Capital Management LLC lifted its position in Oramed Pharmaceuticals by 62.1% in the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock worth $5,334,000 after buying an additional 837,153 shares during the last quarter. Murchinson Ltd. raised its stake in shares of Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after acquiring an additional 320,495 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Oramed Pharmaceuticals in the 3rd quarter worth about $272,000. Renaissance Technologies LLC boosted its stake in shares of Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Institutional investors own 12.73% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday.

Oramed Pharmaceuticals Stock Performance

Shares of ORMP stock opened at $2.36 on Wednesday. The stock has a 50 day moving average price of $2.38 and a 200 day moving average price of $2.41. Oramed Pharmaceuticals Inc. has a 52-week low of $2.00 and a 52-week high of $3.67. The firm has a market capitalization of $95.14 million, a P/E ratio of 21.45 and a beta of 1.67.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.